On June 13 2013, the United States Supreme Court ruled that human genes are products of nature and cannot be patented, a decision which brought an end to Myriad Genetics’ monopoly on BRCA1 and BRCA2 testing. Mutations in BRCA1 or BRCA2 significantly increase an individual’s risk for breast and ovarian cancer. As a result of the Supreme Court’s ruling, several companies, listed below, are now offering BRCA testing, many at a lower price than Myriad. If you have a family history of breast or ovarian cancer and are considering BRCA testing, it is recommended that you first meet with a genetic counselor for a risk assessment. To find a genetic counselor near you, visit the National Society for Genetic Counselors.
BRCA Test Providers:
Upcoming Event at BCC
Understanding the Emotional Impact of a BRCA Diagnosis
Wednesday, February 26
Ariella Goodwine, MFT will hold a discussion about the psychosocial issues that can arise upon learning about one’s genetic predisposition to breast and ovarian cancers.
Register (650) 326-6686 or toll free (888) 222-4401